國光電氣(688776.SH):公司始終將技術創新置於企業發展的首位
格隆匯10月13日丨有投資者向國光電氣(688776.SH)提問:請問公司如何保持技術領先優勢?
國光電氣回覆:公司始終將技術創新置於企業發展的首位,今年上半年公司新申請國內發明專利、實用新型專利及軟件著作權共7項,其中發明專利2項,實用新型專利5項。截至6月30日,公司累計獲得國內發明專利授權41項、實用新型專利授權65項、外觀設計專利2項、軟件著作權2項。公司目前在研項目72項,項目技術水平均為國內先進,有望持續鞏固公司在電真空器件領域和核工業設備領域的技術領先者和標準制定者地位。謝謝您的關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.